The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience
- PMID: 34705189
- DOI: 10.1007/s11060-021-03882-9
The role of single-fraction stereotactic radiosurgery for atypical meningiomas (WHO grade II): treatment results based on a 25-year experience
Abstract
Purpose: To clarify the role of stereotactic radiosurgery (SRS) for atypical meningiomas (AM).
Methods: A retrospective analysis of 68 patients with AM having SRS from 1995 until 2019.
Results: Nineteen patients (28%) had undergone prior external beam radiation therapy (EBRT) (median dose, 54 Gy). The median follow-up period was 52 months. Eighteen (26%), 17 (25%), and 33 (49%) patients received SRS as an upfront adjuvant (≤ 6 months), early salvage (7-18 months), or late salvage treatment (> 18 months), respectively. The 3-, 5-, and 10-year progression-free survivals (PFSs) were 52%, 35%, and 25%, respectively. The 3-, 5-, and 10-year disease-specific survivals were 85%, 78%, and 61%, respectively. Adverse radiation events (AREs) were observed in 12 patients (18%), with increased or new seizures being the most frequent complication (n = 7). Prior EBRT was associated with reduced PFS (HR 5.92, P < 0.01), reduced DSS (HR 5.84, P < 0.01), and an increased risk of ARE (HR 3.31, P = 0.04). Timing of SRS was correlated with reduced PFS for patients having early salvage treatment compared to upfront adjuvant (HR 3.17, P = 0.01) or late salvage treatment (HR 4.39, P < 0.01).
Conclusion: PFS for patients with residual/recurrent AM remains poor despite SRS. Prior EBRT was associated with worse tumor control, higher tumor-related mortality, and an increased risk of ARE. Further study on the timing of SRS is needed to determine if upfront adjunctive SRS improves tumor control compared to salvage SRS.
Keywords: Atypical meningioma; Gamma knife; Grade II meningioma; Meningioma; Radiosurgery; Radiotherapy.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Salvage Stereotactic Radiosurgery for Recurrent WHO Grade 2 and 3 Meningiomas: A Multicenter Study (STORM).Int J Radiat Oncol Biol Phys. 2024 Nov 1;120(3):730-737. doi: 10.1016/j.ijrobp.2024.04.016. Epub 2024 Apr 18. Int J Radiat Oncol Biol Phys. 2024. PMID: 38641234
-
Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas: treatment results on the basis of a 22-year experience.Cancer. 2012 Feb 15;118(4):1048-54. doi: 10.1002/cncr.26362. Epub 2011 Jul 19. Cancer. 2012. PMID: 21773968
-
Radiation Therapy for Residual or Recurrent Atypical Meningioma: The Effects of Modality, Timing, and Tumor Pathology on Long-Term Outcomes.Neurosurgery. 2016 Jul;79(1):23-32. doi: 10.1227/NEU.0000000000001160. Neurosurgery. 2016. PMID: 26645969
-
Stereotactic radiosurgery versus stereotactic radiotherapy in the management of intracranial meningiomas: a systematic review and meta-analysis.Neurosurg Focus. 2019 Jun 1;46(6):E2. doi: 10.3171/2019.3.FOCUS1970. Neurosurg Focus. 2019. PMID: 31153149
-
Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review.Neurosurg Focus. 2019 Jun 1;46(6):E12. doi: 10.3171/2019.3.FOCUS1967. Neurosurg Focus. 2019. PMID: 31153145
Cited by
-
The Immunohistochemical Loss of H3K27me3 in Intracranial Meningiomas Predicts Shorter Progression-Free Survival after Stereotactic Radiosurgery.Cancers (Basel). 2022 Mar 28;14(7):1718. doi: 10.3390/cancers14071718. Cancers (Basel). 2022. PMID: 35406488 Free PMC article.
-
Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis.J Pers Med. 2024 Jul 29;14(8):802. doi: 10.3390/jpm14080802. J Pers Med. 2024. PMID: 39201994 Free PMC article. Review.
-
Anaplastic Meningioma: Clinical Characteristics, Prognostic Factors and Survival Outcome.Brain Tumor Res Treat. 2022 Oct;10(4):244-254. doi: 10.14791/btrt.2022.0030. Brain Tumor Res Treat. 2022. PMID: 36347639 Free PMC article.
-
Long-Term Follow-Up, Treatment Strategies, Functional Outcome, and Health-Related Quality of Life after Surgery for WHO Grade 2 and 3 Intracranial Meningiomas.Cancers (Basel). 2022 Oct 14;14(20):5038. doi: 10.3390/cancers14205038. Cancers (Basel). 2022. PMID: 36291821 Free PMC article.
-
[Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas.Neuro Oncol. 2024 Aug 5;26(8):1526-1535. doi: 10.1093/neuonc/noae067. Neuro Oncol. 2024. PMID: 38553990 Free PMC article. Clinical Trial.
References
-
- Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG (2010) Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 12:520–527. https://doi.org/10.1093/neuonc/nop066 - DOI - PubMed - PMC
-
- Kleihues P, Cavenee WK, International Agency for Research on Cancer (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
-
- World Health Organization, International Agency for Research on Cancer (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon
-
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, World Health Organization, International Agency for Research on Cancer (2016) WHO classification of tumours of the central nervous system. International Agency For Research On Cancer, Lyon
-
- Kshettry VR, Ostrom QT, Kruchko C, Al-Mefty O, Barnett GH, Barnholtz-Sloan JS (2015) Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol 17:1166–1173. https://doi.org/10.1093/neuonc/nov069 - DOI - PubMed - PMC
MeSH terms
LinkOut - more resources
Full Text Sources